Prophase Labs (PRPH)
OTHER OTC:PRPH
Top Page
Prophase Labs
(OTC:PRPH)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.20
â–²(11.11% Upside)
Action:DowngradedDate:01/28/26
The score is held down primarily by weak financial performance (sharp revenue contraction, persistent losses, and negative cash flows) and bearish trend signals (price below major moving averages with negative MACD). Potential upside catalysts from the earnings call and recent financing/listing developments provide some offset, but execution and liquidity/dilution risks remain material.
Positive Factors
Crown Medical collections
Active settlement negotiations and anticipated recoveries from legacy COVID receivables represent a structural deleveraging opportunity. Realizing these collections could materially improve liquidity, reduce reliance on emergency financing, and strengthen the balance sheet for operational continuity over months.
Negative Factors
Sharp revenue decline
A steep multi‑period revenue contraction and deeply negative margins indicate loss of scale and pricing power. Persistently shrinking sales erode the company’s ability to cover fixed costs, fund R&D or commercialization, and sustain competitive positioning over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Crown Medical collections
Active settlement negotiations and anticipated recoveries from legacy COVID receivables represent a structural deleveraging opportunity. Realizing these collections could materially improve liquidity, reduce reliance on emergency financing, and strengthen the balance sheet for operational continuity over months.
Read all positive factors
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$775.22K
Dividend YieldN/A
Average Volume (3M)246.65K
Price to Earnings (P/E)―
Beta (1Y)1.95
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.60
Shares Outstanding9,493,287
10 Day Avg. Volume470,961
30 Day Avg. Volume246,651
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.96
Price to Sales (P/S)2.13
P/FCF Ratio-0.78
Enterprise Value/Market Cap9.90
Enterprise Value/Revenue7.13
Enterprise Value/Gross Profit3.73
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Prophase Labs Business Overview & Revenue Model
Company Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Dia...
How the Company Makes Money
Prophase Labs generates revenue through the commercialization of its pharmaceutical products and therapies. Key revenue streams include direct sales of its proprietary antiviral treatments, licensing agreements for its intellectual property, and c...
Prophase Labs Earnings Call Summary
Earnings Call Date:Nov 19, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 01, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.Positive Updates
Crown Medical Collections Initiative
Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.
Negative Updates
Stock Price and Market Cap Concerns
The company is facing a low market cap of around $12 million and a declining share price, which is affecting investor confidence and creating pressure to maintain Nasdaq compliance.
Read all updates
Q3-2025 Updates
Positive
Negative
Crown Medical Collections Initiative
Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.
Read all positive updates
Company Guidance
During the ProPhase Labs, Inc.'s third-quarter 2025 earnings call, Chairman and CEO Ted Karkus provided several metrics and strategic insights. He emphasized the importance of shareholder voting on a critical proxy, which could impact strategic initiatives. The company is targeting collections of around $150 million in uncollected COVID testing claims, with expectations to net at least $50 million after discounts and fees. Karkus also discussed the potential of the BSmart esophageal cancer test, estimating a target market of $7-14 billion, and highlighted Nebula Genomics' restructuring towards profitability. ProPhase Labs' current market cap stands at approximately $12 million, with 46.1 million shares outstanding. Karkus addressed the possibility of a reverse stock split to maintain Nasdaq compliance, aiming to capitalize on the company's undervalued stock and significant asset potential.Prophase Labs Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.06M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -24.81M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.70M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 65.70M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 405.00K | 678.00K | 4.74M | 17.44M | 17.51M | 8.46M |
| Total Debt | 7.68M | 24.57M | 18.46M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 58.84M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 6.86M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -22.75M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -22.99M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | -40.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 9.66M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Negative
0.18
Price Trends
0.15
Negative
0.87
Negative
2.45
Negative
Market Momentum
-0.03
Negative
28.76
Positive
24.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPH, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.15, and below the 200-day MA of 2.45, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 28.76 is Positive, neither overbought nor oversold. The STOCH value of 24.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPH.
Prophase Labs Risk Analysis
Prophase Labs disclosed 63 risk factors in its most recent earnings report. Prophase Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prophase Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $26.51M | 20.56 | 0.27% | ― | 75.19% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.45M | -10.73 | -40.66% | ― | -1.50% | 80.17% | |
45 Neutral | $29.14M | -0.62 | -107.16% | ― | -15.61% | -68.96% | |
42 Neutral | $775.22K | -0.70 | -404.42% | ― | ― | ― | |
40 Underperform | $3.12M | -0.89 | -93.87% | ― | -0.74% | 81.49% |
* Healthcare Sector Average
PRPH
Prophase Labs
0.08
-4.72
-98.31%
TXMD
TherapeuticsMD
2.29
1.28
126.73%
AYTU
Aytu BioScience
2.72
1.47
118.95%
YCBD
cbdMD
0.81
-1.26
-60.92%
IMCC
IM Cannabis Corp
0.60
-1.17
-66.19%
Prophase Labs Corporate Events
Business Operations and StrategyLegal Proceedings
ProPhase Labs Issues Update on Crown Medical Collections
Negative
Jan 27, 2026
On January 26, 2026, ProPhase Labs, Inc. announced it had issued an operational update on the progress of its Crown Medical Collections initiative, which concerns legacy COVID-19 testing receivables tied to its laboratory subsidiaries that are cur...
Business Operations and StrategyPrivate Placements and Financing
ProPhase Labs Secures Flexible $10 Million Equity Facility
Positive
Jan 23, 2026
On January 16, 2026, ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd., securing access to up to $10 million in equity capital through an at‑the‑company’s‑discretion equity line facility...
Delistings and Listing Changes
ProPhase Labs Announces Uplisting to OTCID Market
Positive
Jan 23, 2026
On January 22, 2026, ProPhase Labs, Inc. announced that its common stock had been approved for uplisting from the Pink Sheets to the OTCID Market. The move marks a significant step in enhancing the company’s trading venue, which may improve ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingStock Split
ProPhase Labs Updates Shareholders Amid Volatility and OTC Move
Negative
Jan 9, 2026
On January 5, 2026, Prophase Labs issued an update to shareholders explaining that recent volatility in its common stock was largely driven by technical factors tied to its capital structure, including an accelerated conversion and resale of most ...
Executive/Board Changes
ProPhase Labs Announces Immediate Resignation of Board Member
Neutral
Jan 9, 2026
On January 5, 2026, ProPhase Labs, Inc. announced that board member Warren Hirsch resigned from the company’s Board of Directors, effective immediately. The company stated that his departure was not due to any disagreement over operations, p...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
ProPhase Labs faces Nasdaq delisting, plans appeal, OTC move
Negative
Jan 2, 2026
On December 29, 2025, ProPhase Labs, Inc. disclosed that it had failed to regain compliance with Nasdaq’s $1.00 minimum bid price requirement by the end of its second 180-day grace period on December 22, 2025, triggering a determination by N...
Business Operations and StrategyM&A Transactions
ProPhase Labs Announces Proposed Reverse Merger with ABL
Positive
Dec 19, 2025
ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological Laboratories S.A., a European biotechnology company, under which ABL would become the majority owner of th...
Delistings and Listing ChangesStock Split
Prophase Labs Implements Reverse Stock Split
Neutral
Dec 12, 2025
On November 30, 2025, Prophase Labs‘ stockholders approved a reverse stock split of its common stock at a ratio of one share for every ten shares, effective December 2, 2025. This move was aimed at increasing the per-share trading price to m...
Business Operations and StrategyShareholder MeetingsStock Split
Prophase Labs Approves Strategic Proposals at Special Meeting
Positive
Nov 26, 2025
On November 24, 2025, ProPhase Labs, Inc. conducted a Special Meeting of Stockholders where six proposals were presented and approved. The proposals included acquiring digital assets, creating a new class of digital treasury shares, issuing digita...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Prophase Labs Secures Forbearance Agreement with Avtech Capital
Neutral
Nov 25, 2025
On November 21, 2025, ProPhase Labs, Inc. received confirmation from Avtech Capital, LLC to continue its forbearance under an existing equipment lease, with a new payment schedule starting November 28, 2025. This arrangement ensures the company ca...
Legal Proceedings
Prophase Labs Faces Unsealed Civil Action Disclosure
Neutral
Nov 25, 2025
On November 21, 2025, ProPhase Labs, Inc. disclosed that a civil action filed against it in 2023 had been unsealed by court order on November 4, 2025. The unsealing is a procedural step under the False Claims Act, and the company was unaware of th...
Business Operations and StrategyLegal ProceedingsM&A TransactionsProduct-Related Announcements
Prophase Labs Unveils Strategic Initiatives and Partnerships
Positive
Nov 19, 2025
On November 19, 2025, ProPhase Labs announced its strategic initiatives, including MA discussions and the commercialization of the BE-Smart™ Esophageal Cancer Test following a landmark study. The company is also pursuing a $50 million collec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.